Terms: = Lung cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
20 results:
1. Inhibition of histone deacetylase 6 destabilizes erk phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction.
Wattanathamsan O; Chantaravisoot N; Wongkongkathep P; Kungsukool S; Chetprayoon P; Chanvorachote P; Vinayanuwattikun C; Pongrakhananon V
J Biomed Sci; 2023 Jan; 30(1):4. PubMed ID: 36639650
[TBL] [Abstract] [Full Text] [Related]
2. Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer.
Dietze R; Hammoud MK; Gómez-Serrano M; Unger A; Bieringer T; Finkernagel F; Sokol AM; Nist A; Stiewe T; Reinartz S; Ponath V; Preußer C; von Strandmann EP; Müller-Brüsselbach S; Graumann J; Müller R
Theranostics; 2021; 11(3):1377-1395. PubMed ID: 33391540
[TBL] [Abstract] [Full Text] [Related]
3. ZCCHC14 regulates proliferation and invasion of non-small cell lung cancer through the MAPK-p38 signalling pathway.
Shi X; Han X; Cao Y; Li C; Cao Y
J Cell Mol Med; 2021 Feb; 25(3):1406-1414. PubMed ID: 33345444
[TBL] [Abstract] [Full Text] [Related]
4. erk phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
Reissig TM; Sara L; Ting S; Reis H; Metzenmacher M; Eberhardt WEE; Zaun G; Herold T; Aigner C; Darwiche K; Stuschke M; Schildhaus HU; Schuler M; Wiesweg M
Lung Cancer; 2020 Nov; 149():10-16. PubMed ID: 32947221
[TBL] [Abstract] [Full Text] [Related]
5. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
[TBL] [Abstract] [Full Text] [Related]
6. Plakophilin 1 is methylated and has a tumor suppressive activity in human lung cancer.
Haase D; Cui T; Yang L; Ma Y; Liu H; Theis B; Petersen I; Chen Y
Exp Mol Pathol; 2019 Jun; 108():73-79. PubMed ID: 30946843
[TBL] [Abstract] [Full Text] [Related]
7. The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis.
Salama Y; Lin SY; Dhahri D; Hattori K; Heissig B
FASEB J; 2019 Mar; 33(3):3465-3480. PubMed ID: 30458112
[TBL] [Abstract] [Full Text] [Related]
8. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract] [Full Text] [Related]
9. PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during lung Tumorigenesis.
Zhou X; Updegraff BL; Guo Y; Peyton M; Girard L; Larsen JE; Xie XJ; Zhou Y; Hwang TH; Xie Y; Rodriguez-Canales J; Villalobos P; Behrens C; Wistuba II; Minna JD; O'Donnell KA
Cancer Res; 2017 Jan; 77(1):187-197. PubMed ID: 27821484
[TBL] [Abstract] [Full Text] [Related]
10. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma.
Biernacka A; Tsongalis PD; Peterson JD; de Abreu FB; Black CC; Gutmann EJ; Liu X; Tafe LJ; Amos CI; Tsongalis GJ
Cancer Genet; 2016 May; 209(5):195-8. PubMed ID: 27068338
[TBL] [Abstract] [Full Text] [Related]
11. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell lung cancer (SELECT-1).
Jänne PA; Mann H; Ghiorghiu D
Clin Lung Cancer; 2016 Mar; 17(2):e1-4. PubMed ID: 26837474
[TBL] [Abstract] [Full Text] [Related]
12. Increased phosphorylation of erk1/2 is associated with worse chemotherapeutic outcome and a poor prognosis in advanced lung adenocarcinoma.
Tsujino I; Nakanishi Y; Hiranuma H; Shimizu T; Hirotani Y; Ohni S; Ouchi Y; Takahashi N; Nemoto N; Hashimoto S
Med Mol Morphol; 2016 Jun; 49(2):98-109. PubMed ID: 26705127
[TBL] [Abstract] [Full Text] [Related]
13. MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer.
He Y; Wang L; Liu W; Zhong J; Bai S; Wang Z; Thomas DG; Lin J; Reddy RM; Ramnath N; Carrott PW; Lynch WR; Orringer MB; Chang AC; Beer DG; Chen G
Sci Rep; 2015 Jun; 5():11471. PubMed ID: 26088427
[TBL] [Abstract] [Full Text] [Related]
14. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract] [Full Text] [Related]
15. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
[TBL] [Abstract] [Full Text] [Related]
16. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.
Han J; Tian R; Yong B; Luo C; Tan P; Shen J; Peng T
Biochem Biophys Res Commun; 2013 Jun; 435(3):493-500. PubMed ID: 23684620
[TBL] [Abstract] [Full Text] [Related]
17. The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/erk pathway in human lung cancer.
Cui T; Chen Y; Yang L; Knösel T; Huber O; Pacyna-Gengelbach M; Petersen I
Carcinogenesis; 2012 Dec; 33(12):2326-33. PubMed ID: 22941060
[TBL] [Abstract] [Full Text] [Related]
18. Gamma-amino butyric acid inhibits the nicotine-imposed stimulatory challenge in xenograft models of non-small cell lung carcinoma.
Al-Wadei HA; Al-Wadei MH; Ullah MF; Schuller HM
Curr Cancer Drug Targets; 2012 Feb; 12(2):97-106. PubMed ID: 22165966
[TBL] [Abstract] [Full Text] [Related]
19. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
Nanjundan M; Byers LA; Carey MS; Siwak DR; Raso MG; Diao L; Wang J; Coombes KR; Roth JA; Mills GB; Wistuba II; Minna JD; Heymach JV
J Thorac Oncol; 2010 Dec; 5(12):1894-904. PubMed ID: 21124077
[TBL] [Abstract] [Full Text] [Related]
20. lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.
Borczuk AC; Kim HK; Yegen HA; Friedman RA; Powell CA
Am J Respir Crit Care Med; 2005 Sep; 172(6):729-37. PubMed ID: 15976377
[TBL] [Abstract] [Full Text] [Related]
